Table 4.

Type and result of surgery, follow-up and complications

Result	Number (%)
Tumor resected	42 (95%)(a)
Primary only	12 (27%)
With lymph node metastases	30 (68%)
With liver metastases	18 (41%)
Type Primary surgery
Enucleation	5 (12%)
Resection	36 (86%)
Partial pancreatectomy	23 (55%)
Whipple resection	10 (23%)
Total pancreatectomy	2 (5%)
Liver resection	19 (45%)
Wedge resection	10 (23%)
Lobectomy	9 (21%)(b)
Vascular reconstruction	9 (21%)
SMV-portal vein	9 (21%)
SMA	1 (2%)
Surgical complications
Surgical death	0 (0%)
Complications	12(28%)(c)
Surgical result
Immediate tumor free	18 (42%)(d)
Recurrence	5 (12%) (d)
Time to recurrence years
Mean ± SEM	1.7 ± 0.6
[range]	[0.5-3]
Long term disease-free	14 (33%)(d)
Status Last follow-up
Alive	34 (77%)
Dead	10 (23%)
Years surgery to death
Mean ± SEM	5.5 ± 0.3
[range]	[3-8]
Duration of follow-up (yrs)
Time from surgery
Mean ± SEM	5.7 ± 1.0
[range]	[1.3-21.2]
Time from diagnosis
Mean ± SEM	12.7 ± 1.2
[range]	[3.9-25.8]
Other anti-tumor treatment	18 (43%)
Chemotherapy	12 (28%)
Other	10 (23%)(e)

^(a)Percentage based on 24 patients who underwent surgical exploration. Two patients had unresectable disease. See Table 3 footnote.

^(b)Include a trisegmentectomy (n=1), l hepatic lobe resection(n=4), and segmentectomy (n=4)

^(c)Complications include postoperative pancreatitis (n=1), abscess (n=4), wound infection (n=3), bile duct injury (n=1), leak at pancreaticojejunostomy (n=2) and ischemic bowel (n=1).

^(d)Disease free status and recurrence based on serial imaging studies as described in Methods

^(e)Patients treated with alpha-interferon (n=2), somatostatin analogues (n=9) or PRRT (n=1). Two that received alpha-interferon also got somatostatin analogues